NEW YORK, February 28, 2017 /PRNewswire/ --
The legal cannabis industry has a very important accomplishment to brag about - job creation. A new research published by New Frontier Data projects that the legal cannabis market will create more than a quarter of a million new jobs by 2020, a bigger number of new jobs than is expected from manufacturing or even the government, according to the Bureau of Labor Statistics. The legal cannabis market was worth an approximately $7.2 billion in 2016 and is projected to grow at a compound annual growth rate of 17%, according to the research. Medical cannabis sales are projected to grow from $4.7 billion in 2016 to $13.3 billion in 2020. Sales of cannabis for recreational use are estimated to increase from $2.6 billion in 2016 to $11.2 billion by 2020. ChineseInvestors.com (OTC: CIIX), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), GW Pharmaceuticals (NASDAQ: GWPH)
Founder and CEO of New Frontier Data, Giadha Aguirre De Carcer, commented, "These numbers confirm that cannabis is a major economic driver and job-creation engine for the U.S. economy." Forbes reported: "While we see a potential drop in total number of U.S. jobs created in 2017, as reported by Kiplinger, as well as an overall expected drop in GDP growth, the cannabis industry continues to be a positive contributing factor to growth at a time of potential decline. We expect the cannabis industry's growth to be slowed down to some degree in the next three to five years, however with projected total market sales to exceed $24 billion by 2025, and the possibility of almost 300,000 jobs by 2020, it remains a positive economic force in the U.S."
ChineseInvestors.com (OTCQB: CIIX) announced yesterday that the "company CEO Warren Wang attended Shangdong Yibao Biologics Co. Ltd.'s annual conference, and, by invitation, delivered a five-minute speech to celebrate the 18th anniversary of Yibao Biologics.
As an attendee of the conference, Wang learned how direct sales of the health products industry operate in China, and how to apply this information to build the sales team of CIIX's ChineseCBDoil.com retail website. "The market for direct selling of natural products in the United States has considerable depth, and varies from the Chinese market in many ways. It was an honor to attend this year's Yibao Biologics conference, where I was able to gain valuable market insight as well as present my own expertise to fellow attendees," says Wang.
ChineseInvestors.com recently launched http://www.ChineseCBDoil.com , marking the company's official entry into the CBD hemp oil markets. "ChineseInvestors.com will continue to sell CBD health products through online retailing methods… we will gradually open offline selling channels and combine word-of-mouth marketing with Internet retailing. Our goal is to benefit more Chinese people with reliable logistics network and commodity channels, as well as to provide leading positions in products and resources. Due to the huge size of the Chinese direct selling market, we hope to further expand our market share through investment and alliance in and with direct selling companies," concludes Wang.
Cara Therapeutics Inc. (NASDAQ: CARA) is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.
Insys Therapeutics Inc. (NASDAQ: INSY) is recognized for its advances surrounding a progressive line of innovative drugs and novel drug delivery systems that improve the quality of patients' lives. The company is currently researching on its cannabidiol oral solution for the treatment of subjects with Prader-Willi Syndrome. The primary objectives of this study are to assess the efficacy of Cannabidiol Oral Solution on hyperphagia-related behavior in subjects with Prader-Willi Syndrome, and to assess the efficacy of Cannabidiol Oral Solution on body weight in subjects with PWS.
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments. Zynerba develops therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of two cannabinoids: cannabidiol, a non-psychoactive cannabinoid, and tetrahydrocannabinol. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing. The Company's CBD gel, ZYN002, is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel.
GW Pharmaceuticals (NASDAQ: GWPH) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms.
Please sign up now at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now. Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. FinancialBuzz.com expects to be compensated five thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information: Media Contact: [email protected], +1-877-601-1879 Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
Advertisement
The legal cannabis industry has a very important accomplishment to brag about - job creation. A new research published by New Frontier Data projects that the legal cannabis market will create more than a quarter of a million new jobs by 2020, a bigger number of new jobs than is expected from manufacturing or even the government, according to the Bureau of Labor Statistics. The legal cannabis market was worth an approximately $7.2 billion in 2016 and is projected to grow at a compound annual growth rate of 17%, according to the research. Medical cannabis sales are projected to grow from $4.7 billion in 2016 to $13.3 billion in 2020. Sales of cannabis for recreational use are estimated to increase from $2.6 billion in 2016 to $11.2 billion by 2020. ChineseInvestors.com (OTC: CIIX), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), GW Pharmaceuticals (NASDAQ: GWPH)
Advertisement
Founder and CEO of New Frontier Data, Giadha Aguirre De Carcer, commented, "These numbers confirm that cannabis is a major economic driver and job-creation engine for the U.S. economy." Forbes reported: "While we see a potential drop in total number of U.S. jobs created in 2017, as reported by Kiplinger, as well as an overall expected drop in GDP growth, the cannabis industry continues to be a positive contributing factor to growth at a time of potential decline. We expect the cannabis industry's growth to be slowed down to some degree in the next three to five years, however with projected total market sales to exceed $24 billion by 2025, and the possibility of almost 300,000 jobs by 2020, it remains a positive economic force in the U.S."
ChineseInvestors.com (OTCQB: CIIX) announced yesterday that the "company CEO Warren Wang attended Shangdong Yibao Biologics Co. Ltd.'s annual conference, and, by invitation, delivered a five-minute speech to celebrate the 18th anniversary of Yibao Biologics.
As an attendee of the conference, Wang learned how direct sales of the health products industry operate in China, and how to apply this information to build the sales team of CIIX's ChineseCBDoil.com retail website. "The market for direct selling of natural products in the United States has considerable depth, and varies from the Chinese market in many ways. It was an honor to attend this year's Yibao Biologics conference, where I was able to gain valuable market insight as well as present my own expertise to fellow attendees," says Wang.
ChineseInvestors.com recently launched http://www.ChineseCBDoil.com , marking the company's official entry into the CBD hemp oil markets. "ChineseInvestors.com will continue to sell CBD health products through online retailing methods… we will gradually open offline selling channels and combine word-of-mouth marketing with Internet retailing. Our goal is to benefit more Chinese people with reliable logistics network and commodity channels, as well as to provide leading positions in products and resources. Due to the huge size of the Chinese direct selling market, we hope to further expand our market share through investment and alliance in and with direct selling companies," concludes Wang.
Cara Therapeutics Inc. (NASDAQ: CARA) is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.
Insys Therapeutics Inc. (NASDAQ: INSY) is recognized for its advances surrounding a progressive line of innovative drugs and novel drug delivery systems that improve the quality of patients' lives. The company is currently researching on its cannabidiol oral solution for the treatment of subjects with Prader-Willi Syndrome. The primary objectives of this study are to assess the efficacy of Cannabidiol Oral Solution on hyperphagia-related behavior in subjects with Prader-Willi Syndrome, and to assess the efficacy of Cannabidiol Oral Solution on body weight in subjects with PWS.
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments. Zynerba develops therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of two cannabinoids: cannabidiol, a non-psychoactive cannabinoid, and tetrahydrocannabinol. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing. The Company's CBD gel, ZYN002, is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel.
GW Pharmaceuticals (NASDAQ: GWPH) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms.
Please sign up now at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now. Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. FinancialBuzz.com expects to be compensated five thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information: Media Contact: [email protected], +1-877-601-1879 Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
